Key result
Gyro C1E3 pump avoids downstream thromboembolism in calves despite internal thrombi forming after 2 days.
Why the study?
Is the mass production model of the Gyro C1E3 centrifugal blood pump safe and feasible for long-term cardiac assist in an ex vivo calf model?
Is the mass production model of the Gyro C1E3 centrifugal blood pump safe and feasible for long-term cardiac assist in an ex vivo calf model?
Answers are grounded in this paper and cite their sources.
The Gyro C1E3 centrifugal blood pump is capable of long-term assist circulation in a calf model, though higher anticoagulation targets (ACT >250 sec) are recommended after 2 days to prevent intra-pump thrombosis.
The Gyro C1E3 is a centrifugal blood pump. Its antithrombogenic and antitraumatic blood features were demonstrated by prior studies. Based upon these studies, a mass production model of the C1E3 is becoming commercially available. Therefore, this feasibility study was conducted using the mass production models of the Gyro C1E3 for long-term cardiac assist in ex vivo animal experiments. Five healthy calves were used and 15 pump heads were applied for different time periods (Group 1, 30 days; Group 2, 14 days; Group 3, 10 and 7 days; Group 4, 4 days; and Group 5, 2 days). Activated clotting time (ACT) was kept at 200-250 sec. All five calves demonstrated neither abnormal signs nor abnormal blood examination data throughout the experiment. During necropsy, no thromboembolism was found in any downstream organs. Groups 1-4 showed thrombi inside the pump heads while two pumps in Group 5 had no thrombi formations. Bearing deformation or possible wear did not increase after 2 days of pumping. The C1E3 is capable of long-term assist circulation. However, after 2 days of pumping, careful observation is necessary since thrombi may occur inside the pump when ACT is controlled under 250 sec. During the weaning stage or low flow (under 2 L/min), over 250 sec of ACT is recommended to assure the safety of the patient.
No takes yet. Share an insight, caveat, or question.
Takano et al. (2000) studied Long-term cardiac assist (n=5). Gyro C1E3 centrifugal blood pump was evaluated on Thrombus formation and bearing deformation. The Gyro C1E3 centrifugal blood pump caused no downstream thromboembolism in 5 calves over up to 30 days, though thrombi formed inside pump heads after 2 days when ACT was 200-250 seconds.
Synapse has enriched 10 related papers. Consider them for comparative context: